---
title: "12 Health Care Stocks Moving In Thursday's Pre-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300028801.md"
description: "During Thursday's pre-market session, healthcare stocks showed significant volatility. Profusa (PFSA) surged 112.5% to $4.36, while GlucoTrack (GCTK) rose 96.55% to $3.99. Other gainers included Surrozen and Pomdoctor. Conversely, Artelo Biosciences (ARTL) fell 30.1%, and Silexion Therapeutics (SLXN) dropped 19.29%. The report highlights major price movements for various NASDAQ-listed healthcare companies."
datetime: "2026-09-24T12:05:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300028801.md)
  - [en](https://longbridge.com/en/news/300028801.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300028801.md)
generator: "portal-rs"
---

# 12 Health Care Stocks Moving In Thursday's Pre-Market Session

### Gainers

-   **Profusa** (NASDAQ:PFSA) stock increased by 112.5% to $4.36 during Thursday's pre-market session. The company's market cap stands at $1.2 million.
-   **GlucoTrack** (NASDAQ:GCTK) stock rose 96.55% to $3.99. The market value of their outstanding shares is at $1.6 million.
-   **Surrozen** (NASDAQ:SRZN) stock increased by 34.62% to $21.76. The company's market cap stands at $189.9 million.
-   **Pomdoctor** (NASDAQ:POM) stock rose 17.48% to $0.94. The company's market cap stands at $7.4 million.
-   **Lite Strategy** (NASDAQ:LITS) stock rose 11.86% to $1.32. The market value of their outstanding shares is at $40.1 million.
-   **Greenland Mines** (NASDAQ:GRML) shares rose 11.52% to $12.48. The market value of their outstanding shares is at $35.5 million.

### Losers

-   **Artelo Biosciences** (NASDAQ:ARTL) stock fell 30.1% to $5.11 during Thursday's pre-market session. The company's market cap stands at $4.0 million.
-   **Silexion Therapeutics** (NASDAQ:SLXN) shares fell 19.29% to $0.25. The company's market cap stands at $1.7 million.
-   **Healthcare Triangle** (NASDAQ:HCTI) shares declined by 15.21% to $0.77. The market value of their outstanding shares is at $1.8 million.
-   **Bullfrog AI Hldgs** (NASDAQ:BFRG) stock declined by 14.31% to $0.81. The company's market cap stands at $17.6 million.
-   **Aclarion** (NASDAQ:ACON) shares fell 14.18% to $2.52. The company's market cap stands at $8.4 million.
-   **Viking Therapeutics** (NASDAQ:VKTX) stock decreased by 12.25% to $36.55. The company's market cap stands at $4.8 billion. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [SRZN.US](https://longbridge.com/en/quote/SRZN.US.md)
- [ARTL.US](https://longbridge.com/en/quote/ARTL.US.md)
- [PFSA.US](https://longbridge.com/en/quote/PFSA.US.md)
- [SLXN.US](https://longbridge.com/en/quote/SLXN.US.md)
- [POM.US](https://longbridge.com/en/quote/POM.US.md)
- [GCTK.US](https://longbridge.com/en/quote/GCTK.US.md)
- [LITS.US](https://longbridge.com/en/quote/LITS.US.md)
- [GRML.US](https://longbridge.com/en/quote/GRML.US.md)
- [HCTI.US](https://longbridge.com/en/quote/HCTI.US.md)
- [BFRG.US](https://longbridge.com/en/quote/BFRG.US.md)
- [ACON.US](https://longbridge.com/en/quote/ACON.US.md)
- [VKTX.US](https://longbridge.com/en/quote/VKTX.US.md)
- [NVACW.US](https://longbridge.com/en/quote/NVACW.US.md)
- [SRZNW.US](https://longbridge.com/en/quote/SRZNW.US.md)
- [GRMLW.US](https://longbridge.com/en/quote/GRMLW.US.md)
- [SLXNW.US](https://longbridge.com/en/quote/SLXNW.US.md)
- [BFRGW.US](https://longbridge.com/en/quote/BFRGW.US.md)
- [ACONW.US](https://longbridge.com/en/quote/ACONW.US.md)

## Related News & Research

- [GlucoTrack Tightens Terms in Recent Financing Amendments](https://longbridge.com/en/news/300356119.md)
- [Silexion Highlights Positive Translational Data for RNAi Oncology](https://longbridge.com/en/news/300312634.md)
- [Surrozen says FDA clears IND for SZN-8141 diabetic macular edema trial](https://longbridge.com/en/news/300788834.md)
- [Blood Pressure Drug Recall Hits Nearly 14,000 Medicines in US Under FDA’s ‘Adverse Health Consequences’ Risk](https://longbridge.com/en/news/300405235.md)
- [Silexion Therapeutics doses first patient in Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer](https://longbridge.com/en/news/300569183.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**